What are the cyclooxygenase (COX) isoforms and how are non‑steroidal anti‑inflammatory drugs (NSAIDs) classified based on their COX selectivity?

COX Classification and NSAID Selectivity

Cyclooxygenase Isoforms

Two distinct cyclooxygenase isoforms exist—COX-1 and COX-2—each with different physiological roles and regulatory mechanisms, forming the basis for classifying NSAIDs by their selectivity. 1

COX-1 (Constitutive Pathway)

• COX-1 is the predominant constitutive enzyme that mediates gastroduodenal cytoprotection, renal perfusion, and platelet activity through prostaglandin synthesis. 1
• Platelets contain only COX-1 and produce thromboxane A2 (TXA2), which promotes platelet aggregation and vasoconstriction. 2
• COX-1-derived prostaglandins increase mucosal blood flow, stimulate mucus and bicarbonate secretion, and promote epithelial proliferation in the stomach. 1

COX-2 (Inducible Pathway)

• COX-2 is inducible by inflammatory stimuli and produces prostaglandins that mediate inflammation, pain, and fever. 1
• Endothelial cells generate prostacyclin (PGI2) primarily through COX-2, which inhibits platelet aggregation and causes vasodilation. 2
• The balance between COX-1-mediated platelet TXA2 and COX-2-mediated endothelial prostacyclin is critical for vascular homeostasis and thrombosis prevention. 2

NSAID Classification by COX Selectivity

COX-1 Selective NSAIDs

• Flurbiprofen and ketoprofen preferentially inhibit COX-1 over COX-2. 3
• Low-dose aspirin (≤325 mg) functions primarily as a COX-1 inhibitor, providing cardioprotection through irreversible platelet inhibition. 1

Non-Selective NSAIDs (Inhibit Both COX-1 and COX-2)

• Ibuprofen and naproxen are essentially non-selective, inhibiting both COX-1 and COX-2 to similar degrees. 3
• These agents cause both anti-inflammatory effects (via COX-2 inhibition) and gastrointestinal toxicity (via COX-1 inhibition). 1

COX-2 Preferential NSAIDs

• Diclofenac and mefenamic acid demonstrate COX-2 selectivity in vitro but still retain sufficient COX-1 activity to inhibit gastric prostaglandin synthesis at therapeutic concentrations. 3
• Diclofenac is as COX-2 selective as celecoxib and carries comparable cardiovascular risk. 4

Highly Selective COX-2 Inhibitors (Coxibs)

• Celecoxib is the only selective COX-2 inhibitor currently available in the United States following the withdrawal of rofecoxib and valdecoxib. 5
• Etoricoxib (not FDA-approved in the US) lies on the highly COX-2-selective end of the spectrum. 6
• Rofecoxib was withdrawn from the market due to increased cardiovascular risk. 4

Clinical Implications of COX Selectivity

Gastrointestinal Risk

• Inhibition of COX-1 blocks gastroprotective prostaglandins, creating an environment susceptible to peptic ulcer formation and serious GI complications. 1
• The "COX-2 hypothesis" proposed that selective COX-2 inhibitors would provide effective pain relief with reduced GI toxicity by sparing COX-1. 1
• However, animal studies demonstrate that both COX-1 and COX-2 must be inhibited for gastric ulceration to occur; selective inhibition of either alone does not cause gastric damage. 1

Cardiovascular Risk (Prothrombotic Imbalance)

• COX-2 inhibitors suppress endothelial prostacyclin synthesis while leaving platelet TXA2 production intact, creating a prothrombotic imbalance that increases risk for myocardial infarction, stroke, and thrombotic events. 2
• The risk of thrombotic cardiovascular events increases proportionally with COX-2 selectivity and the patient's baseline cardiovascular risk. 5, 6
• A meta-analysis demonstrated a statistically significant increase in myocardial infarction risk with COX-2 inhibitors compared to placebo (rate ratio = 1.86; P = 0.0003). 5

Critical Pitfall: Dual COX Inhibition

• Combining low-dose aspirin (COX-1 inhibitor) with a COX-2 inhibitor creates dual COX inhibition, which produces the ulcer risk of a traditional NSAID. 1, 2
• This combination addresses the prothrombotic imbalance by inhibiting platelet TXA2 but substantially increases gastrointestinal bleeding risk. 2
• Approximately 50% or more of chronic coxib users also take aspirin, and this loss of GI safety advantage remains underappreciated by clinicians. 1

Practical Algorithm for NSAID Selection Based on COX Selectivity

For Patients with Cardiovascular Disease or High Risk

• Avoid diclofenac, etoricoxib, and all selective COX-2 inhibitors due to high thrombotic risk. 2
• Use a stepped-care approach: start with acetaminophen, then add low-dose opioids or non-acetylated salicylates before considering NSAIDs. 5, 6
• If an NSAID is required, naproxen is the safest alternative due to lower cardiovascular risk. 4

For Patients with GI Risk Factors

• Consider COX-2 selective agents to reduce GI toxicity, but recognize that even COX-2 selective NSAIDs inhibit gastric prostaglandin synthesis at therapeutic concentrations. 3
• Add proton pump inhibitor (PPI) gastroprotection when using any NSAID, especially with concurrent aspirin. 2
• Avoid combining aspirin with COX-2 inhibitors unless cardiovascular benefit outweighs increased GI bleeding risk. 1

General Principles

• Use the lowest effective dose for the shortest possible duration regardless of COX selectivity. 5, 4
• No currently marketed NSAID, even those that are COX-2 selective, spares gastric COX activity at therapeutic concentrations. 3